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Summary
Background.  —  The  ﬁrst  French  transapical  transcatheter  aortic  valve  implantation  (TAVI)  was
performed  in  July  2007  in  our  department.
Aims.  —  To  report  4-year  outcomes  of  transapical  implantation  with  the  Edwards  transcatheter(TAVI); bioprosthesis.
Transapical Methods.  —  We  prospectively  evaluated  consecutive  patients  who  underwent  transapical
implantation with  an  Edwards  transcatheter  bioprosthesis  between  July  2007  and  October
2011.  Patients  were  not  suitable  for  conventional  surgery  (due  to  severe  comorbidities)  or
transfemoral  implantation  (due  to  poor  femoral  access).
Abbreviations: BAV, balloon aortic valvuloplasty; CABG, coronary artery bypass graft; ICU, intensive care unit; LVEF, left ventricular
ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; PET,
polyethylene terephthalate; PCI, percutaneous coronary intervention; SD, standard deviation; TTE, transthoracic echocardiography.
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Results.  —  Among  61  patients  (59.0%  men),  mean  logistic  EuroSCORE  was  27.5  ±  14.9%  and  mean
age  was  81.0  ±  6.8  years.  Successful  valve  implantation  was  achieved  in  59/61  patients  (96.7%)
of  patients.  The  other  two  patients  required  conversion  to  conventional  surgery  due  to  pros-
thesis  embolization  and  died.  Six  additional  patients  died  in  the  postoperative  period.  Causes
of  perioperative  death  were  two  septic  shocks  (one  of  peritonitis),  two  multi-organ  failure,
one  ventricular  ﬁbrillation  and  one  respiratory  insufﬁciency.  Intraprocedural  stroke  was  not
observed  in  any  patient.  The  actuarial  survival  rates  at  1,  2  and  4  years  were  73.8%,  67.2%  and
41.0%.  During  this  4-year  period,  four  patients  died  of  cardiovascular  events,  but  no  impairment
of  transprosthesis  gradient  was  observed.
Conclusion.  —  Our  series  of  61  patients  who  underwent  transapical  implantation  of  the  Edwards
transcatheter  bioprosthesis  shows  satisfactory  results,  similar  to  other  reports,  considering  the
high  level  of  severity  of  patients  referred  for  this  method.  Transapical  access  is  a  reliable
alternative  method  for  patients  that  cannot  beneﬁt  from  a  transfemoral  approach.
© 2012  Published  by  Elsevier  Masson  SAS.
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Résumé
Contexte.  —  La  première  implantation  franc¸aise  d’une  valve  aortique  transcathéter  (TAVI)  a  été
réalisée dans  notre  service  en  juillet  2007.
Objectif.  —  Nous  rapportons  le  suivi  pendant  quatre  années  de  nos  implantations  transapicales
avec la  bioprothèse  Edwards  transcathéter.
Méthodes.  — De juillet  2007  à  octobre  2011,  nous  avons  évalué  prospectivement  61  patients
consécutifs (EuroSCORE  logistique  :  27,5  ±  14,9  %).  Leur  âge  moyen  était  de  81,0  ±  6,8  ans  et
59,0  %  étaient  des  hommes.  Tous  ces  patients  ont  bénéﬁcié  d’une  implantation  transapicale  de
la  bioprothèse  Edwards  transcathéter.  Tous  ces  patients  avaient  été  récusés  pour  la  chirurgie
conventionnelle  en  raison  de  comorbidités  sévères  et  n’étaient  pas  éligibles  pour  une  implan-
tation  transfémorale  à  cause  de  mauvais  axes  iliofémoraux.
Résultats.  — L’implantation  de  la  valve  a  été  réalisée  avec  succès  chez  96,7  %  des  patients.
Deux patients  ont  nécessité  une  conversion  en  chirurgie  conventionnelle  à  cause  de  la  migra-
tion  de  la  valve  et  sont  morts.  Six  autres  patients  sont  morts  dans  la  période  postopératoire.
Les causes  de  décès  periopératoires  ont  été  :  deux  chocs  septiques  dont  un  avec  péritonite,
deux  défaillances  multiviscérales,  une  ﬁbrillation  ventriculaire  et  une  insufﬁsance  respiratoire.
Aucun  accident  vasculaire  cérébral  per  procédure  n’a  été  observé  chez  aucun  patient.  Le  taux
de  survie  actuarielle  à  un,  deux  et  quatre  ans  a  été  respectivement  de  73,8  %,  67,2  %  et  41,0  %.
Durant  cette  période  de  quatre  ans,  quatre  patients  sont  décédés  de  causes  cardiovasculaires.
Aucune dégradation  du  gradient  transprothétique  n’a  été  observée  durant  cette  même  période.
Conclusions.  —  Notre  série  de  61  implantations  de  la  bioprothèse  transcathéter  Edwards  montre
des résultats  satisfaisants  et  comparables  à  la  littérature,  considérant  le  niveau  élevé  de  gravité
des  patients  proposés  pour  cette  technique.  La  voie  transapicale  est  une  méthode  alternative
ﬁable  pour  les  patients  ne  pouvant  bénéﬁcier  de  la  voie  transfémorale.
© 2012  Publié  par  Elsevier  Masson  SAS.
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n  April  2002,  the  ﬁrst  human  percutaneous  aortic  valve
mplantation was  performed  in  Rouen  [1].  Different
pproaches quickly  became  feasible  and,  despite  the  his-
orical use  of  the  antegrade  transseptal  approach,  the
etrograde approach  became  popular  during  2005,  with
he development  of  the  RetroFlex  catheter  [2].  Due  to
he large  diameter  of  the  ﬁrst  models  of  the  RetroFlex
atheter (22/24  F)  and  the  presence,  in  numerous  patients,
f small-calibre  vessels  or  vascular  disease,  the  idea  of  a
ransapical approach  emerged.  In  2005,  after  an  animal  fea-
ibility study  [3],  the  ﬁrst  patients  were  implanted  via  a
mall anterolateral  mini  thoracotomy  [4,5].  In  July  2007,
he ﬁrst  transapical  implantation  in  France  was  performed
n our  department.  Since  this  time,  61  patients  have  been
t
i
E
pmplanted  using  this  approach.  We  report  the  4-year  out-
omes of  these  patients.
ethods
etween  July  2007  and  October  2011,  61  patients  have
een implanted  using  a  transapical  approach.  A  transfemoral
pproach was  not  appropriate  in  these  patients  due  to  small-
alibre vessels,  vascular  disease  or  porcelain  aorta.  These
onsecutive patients  were  included  in  a  prospective,  single-
entre registry.  All  patients  selected  by  our  multidisciplinary
eam had  severe,  degenerative  aortic  stenosis,  and  were
ncluded according  to  the  inclusion  criteria  of  successive
uropean trials  and  registries  (Partner,  Source,  France2).  All
atients gave  written  informed  consent.
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Table  1  Preprocedural  baseline  data.
All  patients  (n  =  61)
Age  (years)  81.0  ±  6.8
Men 36  (59.0)
Hypertension  48  (78.7)
Diabetes  15  (24.6)
Previous  MI  22  (36.1)
Previous  PCI  23  (37.7)
Previous  CABG 21 (34.4)
Atrial  ﬁbrillation 19 (31.1)
Neoplasia 14 (23.0)
Chest  X-ray 4 (6.6)
Pacemaker  11  (18.0)
Previous  BAV  26  (42.6)
Syncope  3  (4.9)
Porcelain  aorta 12 (19.7)
Previous  stroke 6 (9.8)
Creatinine  (mol/L)  125.2  ±  68.5
Body  surface  area  (m2)  1.78  ±  0.20
≥ NYHA  III 44  (72.1)
Logistic  EuroSCORE  (%) 27.5 ±  14.9
Aortic annulus  diameter  (mm) 21.7 ±  1.4
Mean aortic  gradient  (mmHg)  41.0  ±  13.9
Aortic valve  area  (cm2)  0.68  ±  0.16
PASP (mmHg)  46.1  ±  15.0
LVEF (%)  56.3  ±  13.2
Data are mean ± standard deviation or number (%). BAV: balloon
aortic  valvuloplasty; CABG: coronary artery bypass graft; LVEF:
left  ventricular ejection fraction; MI: myocardial infarction;
NYHA: New York Heart Association; PASP: pulmonary artery
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(Four  years’  experience  of  TAVI  in  Rouen  
The  screening  process  included  transthoracic  echocar-
diography (TTE)  in  all  patients.  An  annulus  diameter  of
18—21 mm  was  considered  appropriate  for  the  23  mm  pros-
thesis and  more  than  21—24.5  mm  for  the  26  mm  prosthesis.
Selective coronary  angiography,  aortoiliac  angiography
and computed  tomographic  iliofemoral  angiography  were
systematically performed.  Patients  with  an  iliofemoral
diameter less  than  7  or  less  than  8  mm  (for  the  23  or  26  mm
SAPIEN valves,  respectively)  or  6  or  6.5  mm  (for  the  23  or
26 mm  SAPIEN  XT  valves,  respectively)  led  to  the  transapical
approach.
Patients and procedure
From  July  2007  to  September  2010,  the  procedures  were
performed using  a  SAPIEN  valve  and  an  Ascendra  1  delivery
system. This  valve  was  made  of  three  bovine  pericardial
leaﬂets sewn  onto  a  stainless  steel  stent  frame  partially
covered with  a  synthetic  polyethylene  terephthalate  (PET)
fabric sealing  cuff.  Thereafter,  the  procedures  were  per-
formed using  an  Ascendra  2  delivery  system  with  a  22  F
internal diameter  sheath  and  a  SAPIEN  XT  valve.  This  valve
uses a  cobalt  chromium  frame.
All  procedures  were  performed  under  general  anaesthe-
sia in  a  conventional  cardiac  surgery  operating  theatre  using
a  mobile  imaging  system  GE  OEC  9900  C-arm.
Before  the  surgical  procedure,  a  TTE  apical  four-chamber
view was  performed  by  the  surgeon  to  check  the  best  access
to the  apex  of  the  left  ventricle.  Depending  on  the  result,  a
small (6—8  cm)  anterolateral  thoracotomy  was  performed  in
the fourth  or  ﬁfth  intercostal  space.  Two  concentric  purse
strings using  2/0  Prolene  were  achieved,  close  to  the  apex,
on the  lateral  wall  of  the  left  ventricle.  After  ventricular
puncture, a  0.035  inch  Amplatz  Extra-Stiff  J-tip  guide
wire (COOK,  Bjaeverskov,  Denmark)  was  placed  through
the native  aortic  valve  into  the  descending  aorta.  In  the
ﬁrst part  of  the  procedure,  a  valvuloplasty  using  a  20  mm
balloon (Edwards,  Irvine,  CA,  USA)  was  performed  under
rapid ventricular  pacing  (180—220  bpm)  using  a  temporary
endocardial right  ventricle  pacing  lead  introduced  through
the femoral  vein.  The  Ascendra  delivery  system  sheath
was introduced  carefully  under  ﬂuoroscopic  control  and
the depth  of  the  device  was  measured  using  radiopaque
markers. Valve  positioning  was  based  on  ﬂuoroscopy  using
annular calciﬁcation  as  a  landmark.  The  prosthesis  was
delivered using  rapid  ventricular  pacing.  Removal  of  the
sheath was  achieved  cautiously  by  gently  tightening  the  two
concentric purse  strings  using  no  rapid  pacing.  The  pacing
lead was  removed  at  the  end  of  the  procedure.
Data collection
Clinical  and  TTE  parameters  were  obtained  at  baseline,  dis-
charge and  1,  2,  3  and  4  years,  and  the  data  were  entered
into our  institutional  database.
Statistical analysisQualitative  variables  are  expressed  as  counts  and  per-
centages; and  quantitative  variables  as  mean  ±  standard
deviation (SD).  All  data  were  analysed  using  SPSS  software
(v17).
P
T
5systolic pressure; PCI: percutaneous coronary intervention.
esults
reprocedural characteristics
atients  characteristics  are  shown  in  Table  1.  Patients  were
lderly,  had  a  high  mean  Logistic  EuroSCORE  (27.5  ±  14.9%),
ny many  had  previous  coronary  artery  bypass  graft  (CABG)
34.4%) or  porcelain  aorta  (19.7%),  contraindicating  con-
entional surgery.  An  important  number  of  patients  had
ndergone balloon  aortic  valvuloplasty  (BAV)  (42.6%),  which
as performed  while  the  patients  waited  for  implantation,
ue to  the  severity  of  clinical  symptoms  during  the  preim-
lantation period.
Baseline  TTE  data  conﬁrmed  the  severity  of  aortic  steno-
is with  a mean  valvular  area  of  0.68  ±  0.16  cm2 (Table  1).
ean aortic  annulus  diameter,  measured  by  TTE,  was
1.7 ±  1.4  mm.  In  the  23  and  26  mm  valve  groups,  the  mean
alues were  20.4  ±  0.9  and  22.9  ±  0.8  mm,  respectively.  Left
entricular ejection  fraction  (LVEF)  was  moderately  altered,
ith a  mean  value  of  56.3  ±  13.2%  (Table  1).  Mitral  regur-
itation was  assessed  as  more  than  grade  1  in  34  patients
55.7%).rocedural outcome
he  prosthesis  was  placed  in  the  appropriate  position  in
9 of  61  patients  (96.7%).  There  was  one  migration  into
144  P.-Y.  Litzler  et  al.
the  left  ventricle  cavity  (due  to  misplacement)  and  one  of
migration into  the  ascending  aorta  (due  to  the  presence  of
a bulging  septum).  These  two  procedures  were  converted
to surgery  using  cardiopulmonary  bypass  with  conventional
replacement of  the  valve.  These  two  patients  died  in  the
early postoperative  period  (1  and  6  days).  Six  more  patients
died during  the  postoperative  period,  at  4,  5,  6,  18,  28
and 40  days,  leading  to  a  perioperative  mortality  of  13.1%.
Causes of  death  were  septic  shock  (one  of  peritonitis)  (n  =  2),
multi-organ  failure  (n  =  2),  ventricular  ﬁbrillation  (n  =  1)  and
respiratory insufﬁciency  (n  =  1).  Intraprocedural  stroke  was
not observed  in  any  patient.  Postoperative  complications
were: 23  infectious  (37.7%),  13  pulmonary  (21.3%),  six  renal
failure (9.8%)  (necessitating  dialysis  in  ﬁve  patients)  and
three neurological  (4.9%).  Mean  duration  in  the  intensive
care unit  (ICU)  was  3.9  ±  4.6  days  and  mean  hospital  stay
was 12.9  ±  8.8  days.
Signiﬁcant aortic  insufﬁciency  was  observed  in  14
patients: nine  grade  2  (14.8%)  and  ﬁve  grade  3  (8.2%).  At
day 7,  mean  LVEF  was  59.2  ±  12.1%.  At  1  month,  the  mean
aortic oriﬁce  areas  were  1.67  ±  0.48  and  1.68  ±  0.49  cm2 for
the 23  and  26  mm  valves,  respectively.
Long-term results
Full  4-year  follow-up  data  are  available  for  all  patients.  As
shown in  Fig.  1,  the  actuarial  survival  rates  at  1,  2  and  4  years
were 73.8%,  67.2%  and  41.0%,  respectively.  Cardiovascular
death occurred  in  four  patients  during  the  ﬁrst  year,  one  dur-
ing the  second  year  and  one  during  the  third  year.  During  the
ﬁrst year,  seven  patients  were  readmitted  for  amputation,
mitral endocarditis,  pulmonary  infection,  chronic  cardiac
insufﬁciency (n  =  2),  diarrhoea  and  hypothyroidism.  During
the second  and  third  years,  one  patient  was  readmitted  for
femur fracture  and  another  for  vomiting.
At  1  year,  the  mean  aortic  oriﬁce  areas  for  the  23  and
26 mm  valves,  respectively,  were  1.8  ±  0.4  and  1.8  ±  0.3
cm2.  At  2  years,  they  were  1.6  ±  0.9  and  1.6  ±  0.9  cm2,
respectively. Evolution  of  the  mean  aortic  transprosthe-
sis gradient  is  shown  in  Fig.  2.  Mortality  in  patients  with
Figure 1. Actuarial survival (n = 61).
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ligure 2. Evolution of mean aortic transprosthesis gradient.
reprocedural  mitral  insufﬁciency  (≤  grade  1  and  >  grade  1)
as 51.8%  and  31.4%  respectively.
iscussion
ne  of  the  key  points  of  this  single-centre  experience
ith transapical  implantation  of  the  Edwards  transcatheter
ortic valve  is  the  elevated  mean  Logistic  EuroSCORE  of
7.5 ±  14.9%.  Compared  with  the  transfemoral  group  in  our
nstitution (Logistic  EuroSCORE  22.8  ±  11.8%),  the  severity
f the  patients  referred  for  the  transapical  approach  has
lready been  highlighted  [4,5].  In  our  group,  the  patients
ho are  contraindicated  for  surgery  by  the  heart  team  are
rst referred  for  transfemoral  implantation,  performed
nder local  anaesthesia.  Only  patients  whose  arterial
ascular accesses  are  not  convenient  are  proposed  for
he transapical  approach.  Many  of  them  are  polyvascular
atients with  coronary  disease.  This  probably  explains
he high  proportion  of  previous  percutaneous  coronary
ntervention (PCI)  (37.7%)  and  CABG  (34.4%)  procedures.
espite the  fact  that  these  associated  pathologies  have  no
irect impact  on  technical  issues  during  the  procedure,  they
ould have  a  huge  inﬂuence  on  postoperative  outcome.
ransapical implantation  of  a  transcatheter  bioprosthesis  is
 thoracic  surgical  procedure  with  chest  opening,  artiﬁcial
entilation and  general  anaesthesia,  and  is  a  more  invasive
echnique than  the  transfemoral  approach.
The  follow-up  of  our  patients,  despite  a  signiﬁcant  num-
er of  ‘minor’  postoperative  issues  such  as  minor  pleural
ffusion, respiratory  insufﬁciency  and  pain,  shows  a  non-
igniﬁcantly different  long-term  survival  compared  to  a
ransfemoral approach  in  our  institution  (78%,  63%,  36%
t one,  2  and  4  years;  P  =  0.670;  data  not  shown).  Similar
esults have  previously  been  reported  by  Johansson  et  al.  in
 series  of  40  patients  with  a  similar  survival  at  1  year  (77%)
6]. Moreover,  our  survival  results  are  in  accordance  with
hose published  by  Walther  et  al.  in  a  larger  series  of  299
atients: 73%,  68%  and  58%  at  1,  2  and  3  years,  respectively
7]. However,  unlike  the  results  from  Kempfert  et  al.  [8],
he presence  of  preprocedural  mitral  regurgitation  (>  grade
) does  not  seem,  in  our  series,  to  have  an  inﬂuence  on
ong-term survival.
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In  our  study,  23.0%  of  patients  had  grade  2  or  3  aortic
insufﬁciency. The  mechanism  of  these  aortic  insufﬁciencies
is mainly  paravalvular,  as  has  been  previously  described  [9].
The long-term  inﬂuence  of  these  paravalvular  leaks  has  not
been  clearly  assessed,  but  could  have  a  role  in  the  evolution
of the  clinical  status  of  patients.
During  this  experience,  we  have  observed  a  signiﬁcant
improvement in  the  delivery  system,  mainly  concerning  the
diameter of  the  sheath,  leading  to  an  easier  procedure
with reduced  myocardial  trauma.  It  is  interesting  to  note
that we  did  not  observe  any  decrease  in  LVEF  between  the
preprocedural measurement  and  the  7-day  post-procedural
measurement (56.3  ±  13.2%  vs.  59.2  ±  12.1%).  Moreover,  16
patients (26.2%)  presented  with  LVEF  <  50%,  and  only  one
patient (6.3%)  in  this  group  died.  However,  in  all  cases,  the
transapical approach  is  an  invasive  procedure.  The  devel-
opment of  other  approaches,  such  as  transaortic  (through
a mini  sternotomy  or  mini  right  thoracotomy  [10,11])  or
subclavian [12]  approaches  could  change  the  criteria  for
the selection  of  patients.  Patients  with  low  or  very  low
LVEF could  be,  in  the  future,  proposed  for  a  transaortic  or
subclavian approach  in  order  to  spare  ventricular  function.
However, redo  of  CABG  or  porcelain  aorta  should  stay  in  the
ﬁeld of  transapical  approach.
As  reported  previously  (Fig.  2),  we  have  not  observed
an increase  in  mean  transprosthesis  gradient  during  the
4 years  of  follow-up.  However,  it  is  important  to  note  that
degeneration of  bioprostheses  usually  occurs  after  5  years  in
surgical series.  The  high  rate  of  mortality  (cardiovascular  or
otherwise) due  to  the  severity  of  comorbidities,  in  all  the
transapical series  reported,  tends  to  hide  early  failures  of
devices.
Conclusions
Our  series  of  61  transapical  implantations  of  Edwards
transcatheter bioprostheses  shows  satisfactory  results,  con-
sidering the  high  level  of  severity  of  patients  referred  for  this
method. The  frailty  of  the  apex  of  the  left  ventricle,  con-
sidered as  a  main  issue  by  many  cardiac  surgeons,  has  not
impaired our  results.  Some  new  surgical  approaches,  such
as transaortic  or  subclavian,  could  lead  to  a  new  distribu-
tion of  the  patients  between  transfemoral  and  other  surgical
approaches. Ten  years  after  the  ﬁrst  human  implantation
of a  transcatheter  bioprosthesis,  a  large,  worldwide  expe-
rience has  been  accumulated.  The  ﬁrst  objective  of  Alain
Cribier has  been  reached,  namely  ‘to  provide  an  alterna-
tive procedure  for  non-surgical  patients’.  The  future  of  this
promising method  has  still  to  be  deﬁned  and  practitioners,
within the  heart  team,  will  have  to  determine  the  best  use
of this  new  tool.
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